Novartis news in 2026: 25 dated events
The latest Novartis event on this page is dated Oct 28, 2026. globenewswire.com reported: Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
PublicPharmaceutical Manufacturing10,000+ employeesnovartis.comLinkedIn
Get Novartis' live signals in Claude or ChatGPT, or by API
What changed at Novartis this week? Use Autobound signals for novartis.com.- Dated events
- 25
- Last 90 days
- 17
- Latest
- Oct 28, 2026
Source: Autobound Signal API · 77 signals tracked for Novartis · updated
News · latest 10
Latest Novartis news
Showing 10 of 25 dated events. The Signal API returns all of them.
Get them with one API call- Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)Novartis initiated a second Phase 2 clinical study evaluating the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in patients with active moderate to severe psoriatic arthritis.
- Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidanceNovartis reported third-quarter net sales of USD 14.5 billion.
- Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrenceNovartis announced positive six-year follow-up results from the Phase III NATALEE trial evaluating Kisqali plus endocrine therapy for stage II and III HR+/HER2- early breast cancer.
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals$7.8B · With Abogen Biosciences
- 3 steps for taking on Novartis in radiopharma: Curium up firstNovartis generated $1.7 billion in revenue from its radioligand therapies Lutathera and Pluvicto in the first half of the year.
- Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)Novartis's drug Cosentyx® (secukinumab) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending it for marketing authorization to treat polymyalgia rheumatica (PMR).
- Novartis to pay $125M for blood-brain barrier crossing platform$125M · With Sironax
- Novartis strengthens Tyrol as a business location with new investments in KufsteinNovartis has invested approximately 1.8 billion Euro in Austria over the past ten years, strengthening its sites in Kundl and Schaftenau.
- Novartis India Receives Detailed Public Statement for ₹552.49 Crore Open OfferNovartis AG has agreed to sell its 70.68% stake in Novartis India Limited to a consortium led by WaveRise Investments Limited for a total consideration of ₹1,445.89 crore.
- Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)Novartis is planning to meet with the FDA to discuss next steps for its delpacibart braxlosiran (del-brax) therapy for facioscapulohumeral muscular dystrophy (FSHD).
Showing 10 of 25 dated events. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Novartis with the Signal API
One POST /v1/companies/enrich call with novartis.com returns Novartis news signals (news), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"novartis.com","signal_types":["news"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.
Same industry
News at related companies
Questions about Novartis news
What is the latest news on Novartis?
What is going on with Novartis?
Is Novartis laying off employees?
Page updated , the date of the newest row on this page.
Source. News articles about the company, one source link per event.
Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.
Data as of .